The Effect of Topical Bevacizumab on Corneal Neovascularization

Ophthalmology

Volumn 115, Issue 6, 2008, Pages

  Kim, Sang Woo ^a   Ha, Byung Jin ^a   Kim, Eung Kweon ^a,b   Tchah, Hungwon ^c   Kim, Tae im ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFECT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETINA PIGMENT EPITHELIOPATHY; SLIT LAMP; TONOMETRY; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CORNEAL NEOVASCULARIZATION; EPITHELIUM, CORNEAL; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 44449119809     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.02.013     Document Type: Article

References (28)

1. Lynch S.S., and Cheng C.M. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41 (2007) 614-625
2. Hosseini H., and Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses 68 (2007) 799-801
3. Chang J.H., Gabison E.E., Kato T., and Azar D.T. Corneal neovascularization. Curr Opin Ophthalmol 12 (2001) 242-249
4. Azar D.T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 104 (2006) 264-302
5. Gan L., Fagerholm P., and Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82 (2004) 557-563
6. Phillips G.D., Stone A.M., Jones B.D., et al. Vascular endothelial growth factor (rhVEGF 165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 8 (1994) 961-965
7. Amano S., Rohan R., Kuroki M., et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39 (1998) 18-22
8. Zondor S.D., and Medina P.J. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 38 (2004) 1258-1264
9. Rosenfeld P.J., Fung A.E., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 (2005) 336-339
10. Bock F., König Y., Dietrich T., et al. Inhibition of angiogenesis in the anterior chamber of the eye. [in German]. Ophthalmologe 104 (2007) 336-344
11. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
12. Manzano R.P., Peyman G.A., Khan P., et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91 (2007) 804-807
13. DeStafeno J.J., and Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125 (2007) 834-836
14. Fernando N.H., and Hurwitz H.I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9 suppl (2004) 11-18
15. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Study: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
16. Abraham-Marin M.L., Cortes-Luna C.F., Alvarez-Rivera G., et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 245 (2007) 651-655
17. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
18. Dua H.S., King A.J., and Joseph A. A new classification of ocular surface burns. Br J Ophthalmol 85 (2001) 1379-1383
19. Volker-Dieben H.J., D'Amaro J., and Kok-van Alphen C.C. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol 15 (1987) 11-18
20. Wu Y., Zhang Q., Ann D.K., et al. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am J Physiol Cell Physiol 286 (2004) C905-C912
21. Bernatchez P.N., Allen B.G., Gélinas D.S., et al. Regulation of VEGF-induced endothelial cell PAF synthesis: role of p42/44 MAPK, p38 MAPK and PI3K pathways. Br J Pharmacol 134 (2001) 1253-1262
22. Tao Y., Bazan H.E., and Bazan N.G. Platelet-activating factor enhances urokinase-type plasminogen activator gene expression in corneal epithelium. Invest Ophthalmol Vis Sci 37 (1996) 2037-2046
23. Watanabe M., Yano W., Kondo S., et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. Invest Ophthalmol Vis Sci 44 (2003) 3332-3338
24. Irigoyen J.P., Muñoz-Cánoves P., Montero L., et al. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56 (1999) 104-132
25. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 82 (1999) 298-304
26. Ratel D., Mihoubi S., Beaulieu E., et al. VEGF increases the fibrinolytic activity of endothelial cells within fibrin matrices: involvement of VEGFR-2, tissue type plasminogen activator and matrix metalloproteinases. Thromb Res 121 (2007) 203-212
27. Chaudhary N.I., Roth G.J., Hilberg F., et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29 (2007) 976-985
28. Zhang S.X., and Ma J.X. Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26 (2007) 1-37